Composition with effect of improving bone mineral density as well as preparation method, application and product thereof

Abstract

The invention provides a composition with an effect of improving bone mineral density as well as a preparation method, application and a product thereof, and belongs to the technical field of bone joint health products. The composition with the effect of improving the bone mineral density comprises the following components in parts by mass: 0.1-70 parts of collagen peptide; 0.01 to 2 parts of casein phosphopeptides; 7-40 parts of milk mineral salt; 0.5 to 40 parts of fructo-oligosaccharide; and 0.01 to 1 part of vitamin D. In the composition provided by the invention, the casein phosphopeptides, the vitamin D, the fructo-oligosaccharide, the collagen peptide and the milk mineral salt can improve bone calcium and bone mineral density through interaction, so that the composition is used for preventing or improving osteoporosis.

Description

Technical Field

[0001] The present invention belongs to the technical field of bone and joint health products, and relates to a composition having the function of improving bone density, and specifically relates to a composition having the function of improving bone density, and a preparation method, application and product thereof. Background Art

[0002] Osteoporosis is the most common bone disease, characterized by decreased bone mass, reduced bone strength, increased bone brittleness and susceptibility to fractures. Many variable and immutable factors, including human aging, lack of exercise, malnutrition, underlying diseases, drug intake and bone loss in menopausal women, can lead to the formation of osteoporosis. In view of this, improving osteoporosis has become an important prerequisite for maintaining bone health. In the past years of research, it has been found that specific nutritional supplements can achieve specific functional goals in regulating or stimulating bone health, thereby playing a therapeutic role. In addition to drugs, nutritional intervention provides a more cost-effective means to deal with bone diseases and the health costs that come with them.

[0003] Collagen peptides are a class of peptide mixtures obtained by partial hydrolysis of collagen. In recent years, they have received extensive scientific attention as a potential oral supplement for the restoration of bone and joint tissues. Collagen peptides can be digested in the intestine, cross the intestinal barrier, enter the circulatory system, be used in metabolic processes in target tissues, and exhibit biological functions at the tissue level, stimulating the synthesis of collagen in the extracellular matrix of cartilage and other tissues, and improving bone metabolism.

[0004] Casein phosphopeptide is a phosphorylated casein-derived peptide, and its core amino acid sequence is a negatively charged amino acid sequence formed by three phosphoserine amino acid residues and two glutamic acid residues. Many studies have shown that casein phosphopeptide can chelate with calcium ions through negatively charged phosphoserine residues to form a soluble complex, thereby effectively inhibiting the formation of phosphate precipitation by calcium ions in the neutral or alkaline environment of the small intestine, and can also increase the retention time of calcium ions in the body, playing a sustained release role.

[0005] Oligofructose is the only functional oligosaccharide with the dual physiological characteristics of super bifidobacterial factor and water-soluble dietary fiber. As an excellent small molecule water-soluble dietary fiber, oligofructose does not precipitate or increase the viscosity of food, and has the physiological effects of regulating gastrointestinal flora and other dietary fibers. Oligofructose can hardly be decomposed by sucrase and maltase, so it cannot be digested and absorbed by the stomach and small intestine, but directly enters the colon and is fermented by intestinal flora to produce organic acids, which lowers the pH in the intestine, forms an acidic environment, and acidifies the contents of the lumen, increasing the solubility of calcium, thereby promoting calcium absorption in the body, or promoting calcium absorption by increasing the content of calcium polypeptide d9k.

[0006] Bones are mainly composed of extracellular matrix proteins and osteocytes. Bone matrix is ​​mineralized under the physiological action of hydroxyapatite, and calcium is the main component of hydroxyapatite. The absorption and effective utilization of calcium significantly affect the quality of bones. Therefore, calcium is also called the life metal of the human body. Calcium supplementation is considered to be the basic medicine for the prevention and treatment of osteoporosis. A large number of studies have shown that calcium supplementation can increase the bone density of bones throughout the body and prevent the loss of bone mass, which may lead to the risk of osteoporosis or fractures. Adequate calcium supplementation is beneficial to stabilize the quality of bones.

[0007] Milk mineral salt, also known as milk calcium, is made from whey through purification, ultrafiltration and drying processes. In addition to being rich in calcium, it also contains protein, lactose and balanced nutrients such as zinc, sodium, potassium and magnesium.

[0008] Compared with calcium supplements such as calcium carbonate, calcium citrate and calcium gluconate that are currently widely used in the food industry, milk mineral salts show excellent "bioavailability". Its calcium-phosphorus content ratio is about 2:1, which is more conducive to human absorption and utilization. Milk mineral salts also have excellent sensory properties and are easy to use together, making them an ideal dietary calcium source.

[0009] Vitamin D is a general term for a group of steroid derivatives. Since its discovery in the early 20th century, it has been considered synonymous with bone health. Vitamin D plays an important role in calcium homeostasis and the development and maintenance of bones. It is widely recommended for preventing rickets, optimizing bone peak and preventing bone loss, and may reduce the risk of osteoporosis and fractures. Vitamin D is generally believed to promote intestinal absorption of calcium, regulate bone mineralization, and increase the activity of osteocytes in bones.

[0010] In summary, collagen peptides, casein phosphopeptides, oligofructose, milk mineral salts and vitamin D can all be used as active substances in osteoporosis. However, the current application of active substances has problems such as low activity, complex formulation, complex preparation process and limited application.

[0011] The invention patent with the publication number CN106578094A discloses a formula milk powder for preventing osteoporosis for the elderly, which contains lactoferrin, hydrolyzed egg yolk powder, casein phosphopeptide and milk mineral salt, and also contains whey protein powder, galacto-oligosaccharide, oligofructose, taurine, linoleic acid, α-linolenic acid, complex vitamins and complex minerals; the complex vitamins include vitamin A, vitamin D, vitamin E, vitamin B1, vitamin B2, vitamin B6, and vitamin C. The addition of milk mineral salt to the formula milk powder of the invention can supplement the calcium required by the human body, and the addition of lactoferrin, hydrolyzed egg yolk powder and casein phosphopeptide can cooperate with milk mineral salt to promote the absorption and utilization of calcium, promote osteoblastic bone formation and inhibit osteoclast bone resorption, and achieve a dynamic balance between the two, thereby delaying and improving the process of osteoporosis and protecting the bone health of the elderly. However, the formula ingredients of the invention are complex, the activity is not high, and the application has limitations.

[0012] The invention patent with the publication number CN113349379A discloses a composition for improving bone health and a preparation method thereof, the composition comprising the following components by weight: 20-55 parts of non-denatured type II collagen; 10-20 parts of enzymatic bone powder; 1-10 parts of hydrolyzed egg yolk powder; 2-10 parts of hydrolyzed casein; 5-20 parts of milk mineral salt; 0.1-3 parts of colostrum alkaline protein; 0.02-0.1 parts of vitamin K2; the preparation method comprises the following steps: weighing non-denatured type II collagen, enzymatic bone powder, hydrolyzed egg yolk powder, hydrolyzed casein, milk mineral salt, colostrum alkaline protein, and vitamin K2, mixing them evenly to obtain a mixture, adding water and stirring evenly to obtain a mixed solution; refining the mixed solution by passing through a colloid mill and a homogenizer in turn, and spray drying the homogenized solution to obtain a composition. The composition of the invention can activate the adsorption activity of osteoblasts, so that calcium supplementation can enter the bone and form bones, and milk mineral salt combined with vitamin K2 can effectively improve the absorption rate of calcium and regulate bone health. However, the composition of the invention has complex ingredients and a complicated preparation process.

[0013] The invention patent with publication number CN118511956A discloses a solid beverage of forest frog collagen peptides and its preparation method and application. The solid beverage contains forest frog collagen peptide powder, collagen peptide, milk mineral salt, arabinose, L-calcium lactate, ginger extract, steviol glycoside, taurine, xylitol, oligomaltosaccharide, maltodextrin, vitamin C, casein phosphopeptide, theanine, edible flavor and stabilizer. The forest frog collagen peptide powder and the polypeptide components in the collagen peptide in the solid beverage have the effects of anti-oxidation and promoting bone growth; calcium lactate, forest frog collagen peptide powder and milk mineral salt provide a large amount of calcium ions, providing a good nutritional environment for bone growth. However, the composition formula of the invention is complex, and plant extracts are also introduced, which has poor stability and complicated preparation process.

[0014] Therefore, the compositions disclosed above all have certain effects of improving osteoporosis or increasing bone density, but they do not completely solve the problems of low activity, complex components, and certain limitations. Summary of the invention

[0015] The present invention aims to solve the problems in the prior art and provides a composition having the function of improving bone density, and a preparation method and application thereof. The present invention adopts casein phosphopeptide, vitamin D, oligofructose, collagen peptide and milk mineral salt to interact with each other to improve bone calcium and bone density, and can be used to prevent or improve osteoporosis and improve bone density.

[0016] To achieve the above purpose, the technical solution adopted by the present invention is as follows:

[0017] In a first aspect, the present invention provides a composition having the effect of improving bone density, comprising the following components in parts by weight:

[0018]

[0019]

[0020] In the composition, the collagen peptide can be any commercially available product, which is not limited here. The collagen peptide is a product with a relative molecular mass of less than 10000 obtained by extraction, hydrolysis and refining from fresh animal tissues rich in collagen (including skin, bones, tendons, tendons, scales, etc.). The mass fraction of collagen peptide is preferably 0.1-65 parts, more preferably 40-57 parts, more preferably 45-55 parts, and most preferably 51 parts.

[0021] In one embodiment, the collagen peptides are derived from animal bones, and among the collagen peptides, the proportion of bone collagen peptides with a relative molecular mass of less than 10,000 is ≥ 90%.

[0022] In one embodiment, the collagen peptides are derived from bovine bones; the mass proportion of the collagen peptides with a relative molecular mass lower than 10,000 in the collagen peptides is 92.78%.

[0023] In one embodiment, the collagen peptide is selected from the group consisting of collagen peptides The collagen peptide It is a specific collagen peptide with an average molecular weight of about 5kDa, which is derived from the specific hydrolysis of collagen. It has been proven in multiple clinical trials that it can significantly increase bone density and help improve bone stability. The collagen peptide in the composition of the present invention is preferably collagen peptide The collagen peptide can stimulate connective tissue cells, target and regulate the metabolism of the body's own collagen, and work together with the calcium supplement ingredient milk mineral salt and the ingredients that promote calcium absorption, casein phosphopeptide, vitamin D and oligofructose to significantly increase bone calcium and bone density.

[0024] In the composition, the mass fraction of casein phosphopeptide is preferably 0.14-1.21 parts, more preferably 0.16-0.30 parts, and more preferably 0.21 parts. The casein phosphopeptide can be obtained by enzymatic hydrolysis or biological fermentation of bovine casein, or it can be a common commercial product, which is not limited here. In one embodiment, in the composition, the casein phosphopeptide is a casein phosphopeptide with a purity of 80%, and the mass fraction of the casein phosphopeptide is preferably 0.18-1.21 parts, more preferably 0.20-0.30 parts, and more preferably 0.26 parts.

[0025] In one embodiment, the casein phosphopeptide is derived from hydrolyzed casein peptide, and the mass percentage of casein phosphopeptide in the hydrolyzed casein peptide is ≥3.5%, which can be 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5% or 3.5%.

[0026] Casein phosphopeptide has multiple functions such as promoting mineral absorption, preventing tooth decay, promoting bone health, improving body immunity, etc. The composition of the present invention promotes calcium absorption and improves bone calcium and bone density by combining casein phosphopeptide with collagen peptide, milk mineral salt, vitamin D, and oligofructose, and can be used to prevent or improve osteoporosis.

[0027] In the composition, the mass fraction of milk mineral salt is preferably 12.2-20.5 parts, more preferably 17-19 parts, and most preferably 17.6 parts. The milk mineral salt can be any commercially available product, which is not limited here. In one embodiment, the milk mineral salt is derived from cow's milk, and the mass percentage of calcium in the milk mineral salt is 23-28%. The milk mineral salt in the combination group includes the nutrient calcium, which can be used as a calcium supplement component, and acts together with casein phosphopeptide, vitamin D, oligofructose, and collagen peptide that promote calcium absorption, significantly improving bone calcium and bone density.

[0028] In the composition, the mass fraction of oligofructose is preferably 3.73-11.65 parts, more preferably 4-5 parts, and most preferably 4.61 parts. The oligofructose can be any commercially available product, which is not limited here. In one embodiment, the oligofructose is derived from chicory, and the purity of the oligofructose is 93.2-97.5%. The oligofructose acts together with casein phosphopeptide and collagen peptide to significantly improve bone calcium and bone density.

[0029] Preferably, the mass ratio of the collagen peptide, casein phosphopeptide and oligofructose is 0.1-70:0.01-2:0.5-30, preferably 40-57:0.14-1.21:3.73-11.65, more preferably 45-55:0.16-0.30:4-5, and most preferably 51:0.26:4.61. The components interact with each other and can significantly improve bone calcium and bone density.

[0030] In the composition, the vitamin D is selected from vitamin D or a substance containing vitamin D, the vitamin D includes vitamin D2 and / or vitamin D3, and the substance containing vitamin D is selected from mushroom powder. In one embodiment, the vitamin D is selected from vitamin D3, and the active ingredient content in vitamin D3 is 100000IU / g. The vitamin D3 can be any commercially available product, which is not limited here. The mass fraction of vitamin D is preferably 0.04-0.4 parts, more preferably 0.04-0.1 parts, and most preferably 0.04 parts. The present invention can be used to prevent or improve osteoporosis by combining vitamin D with casein phosphopeptide, collagen peptide, oligofructose, and milk mineral salt to supplement calcium, promote calcium absorption, and increase bone calcium and bone density.

[0031] Preferably, in the composition, the mass ratio of collagen peptides, casein phosphopeptides, milk mineral salts, oligofructose and vitamin D is 0.1-70:0.01-2:7-30:0.5-30:0.01-0.5, preferably 40-57:0.14-1.21:12.2-20.5:0.5-30:0.04-0.4, more preferably 45-55:0.16-0.30:17-19:3.73-11.65:0.04-0.4, and most preferably 51:0.21:17.6:4.61:0.04.

[0032] In one embodiment, the composition further includes auxiliary materials, which are commonly used auxiliary materials and can be one or more of food additives and fruit and vegetable powders. The food additives include but are not limited to: nutritional enhancers, preservatives, antioxidants, flavor enhancers, thickeners, acidity regulators, emulsifiers, and colorants. The fruit and vegetable powders include but are not limited to: coconut milk powder, mango powder, orange powder, strawberry powder, banana powder, and passion fruit powder.

[0033] In one embodiment, the composition further comprises auxiliary materials, which include one or more of food additives and fruit and vegetable powders. The food additives include sweeteners and thickeners. The fruit and vegetable powders include coconut milk powder. The sweeteners include erythritol and / or mogroside, and the thickeners include xanthan gum.

[0034] In one embodiment, the composition further comprises auxiliary materials, wherein the auxiliary materials comprise coconut milk powder, erythritol, mogroside and xanthan gum, wherein the mass ratio of erythritol to mogroside is 1:1.

[0035] In one embodiment, the composition further includes auxiliary materials, and the weight percentage of the auxiliary materials is 5-45 parts, preferably 10-30 parts, and more preferably 20-25 parts.

[0036] In one embodiment, the composition further includes auxiliary materials, including fruit and vegetable powder, xanthan gum and sweetener, wherein the fruit and vegetable powder includes coconut milk powder, the mass fraction of coconut milk powder is 5-25 parts, preferably 8-15 parts, and more preferably 10 parts; the mass fraction of xanthan gum is 0.1-2 parts, preferably 0.2-1 parts; the mass fraction of sweetener is 0.5-15 parts, preferably 5-10 parts, and more preferably 10 parts.

[0037] In a second aspect, the present invention provides a method for preparing the composition described in the above technical solution, comprising:

[0038] The components are mixed to obtain the composition having the effect of improving bone density.

[0039] In a third aspect, the present invention provides an application of the composition described in the above technical solution or the composition prepared by the preparation method described in the above technical solution in the preparation of a product for preventing or improving osteoporosis.

[0040] In a fourth aspect, the present invention provides a product for preventing or improving osteoporosis, comprising the composition described in the above technical solution or a composition prepared by the preparation method described in the above technical solution.

[0041] Compared with the prior art, the present invention has the following beneficial effects:

[0042] First, in the composition provided by the present invention, the collagen peptide can stimulate connective tissue cells and target the metabolism of the body's own collagen. It can work together with casein phosphopeptide, oligofructose, vitamin D, and milk mineral salts to supplement calcium components, promote calcium absorption, and regulate the body's own collagen metabolism, thereby achieving the effect of increasing bone calcium and bone density, and can be used to prevent or improve osteoporosis.

[0043] Secondly, in the composition provided by the present invention, the collagen peptides, casein phosphopeptides and oligofructose are in the mass ratio range of 0.1-70:0.01-2:0.5-40, and the components interact with each other, which can supplement calcium components, promote calcium absorption, regulate endogenous collagen metabolism, and significantly improve bone calcium and bone density, and alleviate weight gain caused by decreased estrogen levels.

[0044] Thirdly, the composition provided by the present invention has good stability and low moisture absorption rate, and can be stored for a long time, thereby extending the shelf life. DETAILED DESCRIPTION

[0045] It is worth noting that, unless otherwise specified, the raw materials used in the present invention are all common commercially available products, and their sources are not specifically limited.

[0046] The following sources of raw materials are provided for illustrative purposes:

[0047] Collagen Peptides: Collagen Peptides Gelida;

[0048] Casein phosphopeptide: Shanghai Kanglang Biotechnology Co., Ltd., purity specification: BR, 80%;

[0049] Milk mineral salt: Guangzhou Huijian Biotechnology Co., Ltd., catalog number: 20181016-27;

[0050] Fructooligosaccharide: Baolingbao Biotechnology Co., Ltd.

[0051] Vitamin D3: Vitamin D3 powder, Zhejiang Compuda Biotechnology Co., Ltd.

[0052] Examples 1-5

[0053] According to the formula in Table 1, collagen peptides, casein phosphopeptide, milk mineral salt, oligofructose and vitamin D3 were weighed and mixed evenly to obtain a composition having the effect of improving bone density.

[0054] Table 1 Composition formula having the effect of improving bone density

[0055]

[0056]

[0057] Comparative Example 1

[0058] The difference from Example 1 is that the "collagen peptide" in Example 1 is replaced with the same mass fraction of "casein phosphopeptide" to obtain a composition with the effect of improving bone density.

[0059] Comparative Example 2

[0060] The difference from Example 1 is that the "51 parts of collagen peptide, 0.26 parts of casein phosphopeptide, 4.61 parts of oligofructose" in Example 1 is replaced by "20 parts of collagen peptide 35.5 parts of casein phosphopeptide, 0.37 parts of oligofructose", to obtain a composition having the effect of improving bone density.

[0061] Comparative Example 3

[0062] The difference from Example 1 is that the "51 parts of collagen peptides, 0.26 parts of casein phosphopeptides, and 4.61 parts of oligofructose" in Example 1 are replaced with "18 parts of collagen peptides, 28 parts of casein phosphopeptides, and 9.87 parts of oligofructose" to obtain a composition with the effect of improving bone density.

[0063] Comparative Example 4

[0064] The composition for improving bone density is composed of the following components in parts by weight:

[0065] 19 parts collagen peptides, 6.7 parts casein phosphopeptides, 46 parts milk mineral salts, 0.3 parts oligofructose, 1.51 parts vitamin D3.

[0066] The components were mixed uniformly according to the method of Example 1 to obtain a composition having the effect of improving bone density.

[0067] Test Example 1

[0068] Refer to the "Health Food Function Test and Evaluation Method (2023 Edition)" to test body weight, bone calcium content and bone density. The specific steps are as follows:

[0069] 110 healthy SPF female SD rats were selected, with a body weight of about (250 ± 15g). After 5 days of adaptive feeding, the 110 rats were randomly divided into 11 groups, 10 rats in each group, namely, sham operation group, model group, Example 1-5 group and Comparative Example 1-4 group. Except for the sham operation group, all other groups of rats underwent bilateral ovariectomy. The sham operation group was operated by the same surgical method, but the ovaries were not removed. After surgery, the sham operation group and the model group rats were given free drinking water every day in addition to normal diet. The Example 1-5 group and the Comparative Example 1-4 group were given 0.2g / d (equivalent to 5 times the recommended dose for humans) of the composition of Example 1-5 and Comparative Example 1-4 by gavage every day in addition to normal diet and drinking water, and the feeding time lasted for 3 months. Then the following measurements were performed:

[0070] 1. Body weight measurement:

[0071] After fasting for 12 hours, body weight was measured.

[0072] The results are shown in Table 2. The results show that after ovariectomy in rats, estrogen levels decreased and body weight increased. Compared with the model group, the body weights of rats treated with the compositions of Examples 1 to 5 of the present invention were significantly reduced.

[0073] Table 2 Results of rat body weight measurement

[0074] Group Initial body weight (g) Weight at 3rd month (g) Sham operation group 252.68±10.04 335.05±15.53 Model Group 253.71±11.21 396.35±7.26 Example 1 251.45±9.35 <![CDATA[355.62±22.91 ** ]]> Example 2 250.65±11.07 <![CDATA[363.82±13.42 * ]]> Example 3 245.36±12.23 <![CDATA[361.25±9.26 * ]]> Example 4 249.41±10.22 <![CDATA[370.62±13.92 * ]]> Example 5 251.85±9.11 <![CDATA[372.62±15.19 * ]]> Comparative Example 1 250.51±10.57 392.83±14.21 Comparative Example 2 250.79±12.65 385.76±13.99 Comparative Example 3 255.65±11.38 377.82±11.75 Comparative Example 4 249.69±10.25 390.96±13.92

[0075] Note: *Represents significant difference compared with the model group, p<0.05; ** Indicates significant difference compared with the model group, p < 0.01.

[0076] 2. Bone calcium determination

[0077] (1) Sample collection and preparation

[0078] The left femur of the rat was dried in an oven at 105°C to constant weight, and then the dry weight of the bone was weighed and placed in a conical flask for digestion.

[0079] (2) Sample digestion

[0080] According to the calcium content in the sample, accurately weigh 0.5g, place it in a 150mL conical flask, cover it with a small funnel, add 15mL of mixed acid (nitric acid: perchloric acid = 4:1), and heat and digest on a hot plate until white smoke appears and it is transparent and colorless. If the acid solution is insufficient, add a small amount of mixed acid.

[0081] When the digestion solution is transparent and colorless, add several milliliters of deionized water and boil to remove the remaining acid. Repeat twice. The final volume of the digestion solution should not exceed 1mL. When digesting the sample, a blank test should be performed at the same time. Add the same volume of mixed acid as when digesting the sample and digest under the same conditions.

[0082] (3) Determination

[0083] Bone calcium content was determined by atomic absorption spectrometry.

[0084] The results of bone calcium content determination are shown in Table 3. The results show that after ovariectomy in rats, estrogen levels decreased and bone calcium content decreased. Compared with the model group, the bone calcium content of rats treated with the compositions of Examples 1-5 of the present invention was significantly increased. The bone density of rats treated with the compositions of Example 1 and Comparative Examples 1-4 was compared, and it was found that the milk mineral salts, collagen peptides, hydrolyzed casein peptides, vitamin D3 and oligofructose in the composition of the present invention acted together to significantly increase the bone calcium content, which can be used to improve osteoporosis.

[0085] Table 3 Results of rat bone calcium determination

[0086] Group Bone calcium content (mg / g) Sham operation group 265.1±20.4 Model Group 204.2±15.9 Example 1 <![CDATA[261.2±11.2 ** ]]> Example 2 <![CDATA[254.8±22.3 * ]]> Example 3 <![CDATA[252.1±21.4 * ]]> Example 4 <![CDATA[243.2±19.5 * ]]> Example 5 <![CDATA[246.4±17.1 * ]]> Comparative Example 1 218.5±15.0 Comparative Example 2 233.8±11.7 Comparative Example 3 237.2±18.5 Comparative Example 4 220.9±19.3

[0087] Note: * Represents significant difference compared with the model group, p<0.05; ** Indicates significant difference compared with the model group, p < 0.01.

[0088] 3. Bone density measurement:

[0089] The bone density of the femur center and distal end was measured using a bone densitometer.

[0090] (1) Mark the distal end of the femur and the midpoint of the femur to determine the measurement points.

[0091] Determination of the femoral midpoint measurement point: Measure the entire length of the femur, pass through its midpoint, and draw a straight line along the cross-sectional direction. This is the femoral midpoint measurement point (cross section).

[0092] Determination of the measurement point of the distal end of the femur: Determine the measurement point at the lowest edge of the distal end of the femur joint groove. Through this point, draw a straight line parallel to the mark at the midpoint of the femur mentioned above. This is the measurement point (cross section) of the distal end of the femur.

[0093] (2) Calibrate the instrument using a bone model before measurement.

[0094] (3) After calibration, continue to measure the bone model and compare it with its standard value. The error shall not exceed 3%.

[0095] (4) Bone densitometer parameter setting:

[0096] Measurement method: precision; Number of scans: 2 times; Scanning mode: automatic; Detection threshold: 99%.

[0097] (5) Measure bone density at the midpoint and distal end of the femur

[0098] Take the right femur of the rat as the bone to be tested, and place the bone to be tested on the measuring table perpendicular to the moving direction of the bone densitometer probe; move the bone to be tested so that the marking line of the test point coincides with the vertical projection of the moving track of the probe on the measuring table. Start measuring, and each point should be measured twice. If the two results are not parallel (the error is greater than 10%), the measurement should be repeated. Take the average of the two results, divide BMC (bone mineral content) by BW (bone width), and the result is BMD (bone density).

[0099] The results of bone density measurement are shown in Table 4. The results show that after the ovariectomy of rats, the estrogen level decreased, the bone density of the femur center point and the femur distal end decreased. Compared with the model group, the bone density of rats treated with the compositions of Examples 1-5 of the present invention was significantly improved. The bone density of rats treated with the compositions of Example 1 and Comparative Examples 1-4 was compared, and it was found that the milk mineral salts, collagen peptides, hydrolyzed casein peptides, vitamin D3 and oligofructose in the composition of the present invention can significantly improve bone density, and can be used to improve osteoporosis.

[0100] Table 4 Results of bone density determination in rats

[0101]

[0102]

[0103] Note: *Represents significant difference compared with the model group, p<0.05; ** Indicates significant difference compared with the model group, p < 0.01.

[0104] Test Example 2

[0105] The auxiliary materials were added to the compositions of Examples 1-5 and Comparative Examples 1-4 respectively to obtain compositions containing auxiliary materials. The auxiliary materials were 10 parts of coconut milk powder, 0.75 parts of xanthan gum and 10 parts of sweetener (the mass ratio of erythritol to mogroside was 1:1).

[0106] Take a glass desiccator with a supersaturated NaCl solution at the bottom, and place 9 weighing bottles in the desiccator to reach constant weight in a constant temperature drying oven at 25°C. Take 1g of the composition containing the excipients respectively, put it in a weighing bottle, weigh it accurately, open the weighing cover, put it in the upper part of the desiccator, store it in a constant temperature drying oven at 25°C, weigh it after 15 days, and calculate the moisture absorption rate of different samples.

[0107] Moisture absorption rate (%) = (weight of composition after 15 days - initial weight of composition) / initial weight of composition * 100%

[0108] The results are shown in Table 5, which show that after the same auxiliary materials are added to the composition of the present invention, the moisture absorption rate is low, the stability is good, and the composition can be stored for a long time, thereby extending the shelf life.

[0109] Table 5 Hygroscopicity results of the compositions containing excipients

[0110]

[0111]

[0112] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.

Claims

1. A composition having the effect of improving bone density, characterized in that: The composition includes the following components in parts by weight:

2. The composition according to claim 1, characterized in that The mass ratio of the collagen peptide, casein phosphopeptide and oligofructose is 0.1-70:0.01-2:0.5-40.

3. The composition according to claim 2, characterized in that The mass ratio of the collagen peptide, casein phosphopeptide and oligofructose is 40-57:0.14-1.21:3.73-11.

65.

4. The composition according to claim 3, characterized in that The mass ratio of the collagen peptide, casein phosphopeptide and oligofructose is 45-55:0.16-0.30:4-5.

5. The composition according to claim 1, characterized in that The vitamin D is selected from vitamin D or a substance containing vitamin D, the vitamin D includes vitamin D2 and / or vitamin D3, and the substance containing vitamin D is selected from mushroom powder.

6. The composition according to claim 5, characterized in that The mass ratio of collagen peptide, casein phosphopeptide, milk mineral salt, oligofructose and vitamin D is 0.1-70:0.01-2:7-40:0.5-40:0.01-0.

5.

7. The composition according to claim 1, characterized in that The composition further includes auxiliary materials.

8. The method for preparing the composition according to any one of claims 1 to 7, characterized in that: include: The components are mixed to obtain the composition having the effect of improving bone density.

9. Use of the composition according to any one of claims 1 to 7 or the composition prepared by the preparation method according to claim 8 in preparing a product for preventing or improving osteoporosis.

10. A product for preventing or improving osteoporosis, characterized in that: include: The composition according to any one of claims 1 to 7 or the composition prepared by the preparation method according to claim 8.

Images